REZOLUTE INC. - COMMON STOCK (NV)

Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting

23 أبريل 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)

06 مارس 2024 06:30:00 بحسب Nasdaq GlobeNewswire

Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update

13 فبراير 2024 15:05:00 بحسب Nasdaq GlobeNewswire

Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer

24 يناير 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

23 يناير 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism

14 ديسمبر 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)

13 ديسمبر 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Rezolute to Participate in BTIG’s 3rd Annual Ophthalmology Day

17 نوفمبر 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Rezolute Reports First Quarter Fiscal 2024 Results

13 نوفمبر 2023 15:05:00 بحسب Nasdaq GlobeNewswire

Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism

17 أكتوبر 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism

11 أكتوبر 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress

14 سبتمبر 2023 15:05:00 بحسب Nasdaq GlobeNewswire

Rezolute to Participate in Upcoming Investor Conferences in September

06 سبتمبر 2023 06:00:00 بحسب Nasdaq GlobeNewswire

Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism

27 يونيو 2023 15:05:00 بحسب Nasdaq GlobeNewswire

Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress

11 مايو 2023 15:05:01 بحسب Nasdaq GlobeNewswire

Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema

23 مارس 2023 15:50:08 بحسب Nasdaq GlobeNewswire

Rezolute to Highlight RZ402 Phase 2 Clinical Program with Leading Clinical Expert

08 مارس 2023 06:00:02 بحسب Nasdaq GlobeNewswire

Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress

10 فبراير 2023 15:05:00 بحسب Nasdaq GlobeNewswire

Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema

15 ديسمبر 2022 06:00:00 بحسب Nasdaq GlobeNewswire

Rezolute Reports First Quarter Fiscal 2023 Results and Highlights Company Progress

09 نوفمبر 2022 15:05:02 بحسب Nasdaq GlobeNewswire